Navigation Links
Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
Date:10/20/2008

are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included in Item 1 of the Quarterly Report on Form 10-QSB for the quarter ending June 30, 2007.

For additional information, please see:

http://www.Lixte.com

EquityGroups.com

http://www.equitygroups.com/otcbb/lixt.html

For Investor Information, please contact:

Jane Trigg

631-830-7092


'/>"/>
SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
2. Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
3. Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
4. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
5. SourceSolution Announces the Launch of Its Initiative to Simplify Outsourcing Decisions for Biotechnology and Pharmaceutical Companies
6. Vineland Welcomes Dr. Daryl Somers as Research Chair, Molecular Breeding and Biotechnology
7. BIO Ventures for Global Health Receives $7 Million Grant from Gates Foundation to Engage Biotechnology in the Fight Against Neglected Diseases of the Developing World
8. Monsanto Recognized as Top Biotechnology Employer by Science Magazine
9. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
10. Jacobs Receives Contract From Gedeon Richter for New Biotechnology Facility in Hungary
11. InNexus Biotechnology CEO to Present at BioContactQuebec 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... ATLANTA , Aug. 28, 2014   SunTrust ... of three industry veterans to its equity research ... "Our ongoing expansion in equity research demonstrates ... with unique insights to enhance their investment decision ... Equities at STRH.  "We continue to make significant ...
(Date:8/28/2014)... Aug. 28, 2014  Armetheon, Inc. ( www.armetheon.com ... mid- to late-stage cardiovascular drug candidates, today announced ... first round of financing. The Series A round ... Bioventures with participation from investors that included Atheneos ... Dr. Larry Hsu , the founder of ...
(Date:8/28/2014)... 27, 2014 Scientists, researchers, and technologists ... SPIE Laser Damage 2014 symposium. Marking its 46th ... lasers will run 14-17 September. The event is sponsored ... photonics . , The premier conference for basic and ... to optical materials will engage researchers and engineers from ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Earlier this ... University in partnership with the U.S. Air Force ... biofuel. The results indicated that this type of fuel ... feedstock and will be important to America’s Eco friendly ... now has a mandate to become independent of foreign ...
Breaking Biology Technology:SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5
... - Non-responder and Null Responder HCV patients -- ... -BRISBANE, Calif., April 21 InterMune, Inc. (Nasdaq: ... innovative clinical study of protease inhibitor ITMN-191 (R7227) ... referred to as the INFORM-1 study, has been ...
... Response Data from Dose-Escalation Study Presented at , ... 2009 -SOUTH SAN FRANCISCO, Calif. and DENVER, April ... PARD ), a biopharmaceutical company focused on oncology, ... a Phase 1 dose-escalation study of picoplatin in ...
... Data on novel pro-apoptotic agent presented at the ... Cancer Research -- University of Pennsylvania ... lines, highlighting AT-101,s inhibition of Mcl-1, also presented ... announced today that the results of preclinical studies ...
Cached Biology Technology:INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients 2INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients 3INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients 4INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients 5Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer 2Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer 3Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer 4Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer 5Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models 2Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models 3
(Date:8/28/2014)... Mayo Clinic researcher and his collaborators have developed an ... the process of re-engineering cells for biomedical investigation. CellNet ... methods to aid stem cell engineering. Details of CellNet ... in two back-to-back papers in the journal Cell ... of uses for all types of cell-based investigations and ...
(Date:8/28/2014)... (Maximizing Access to Research Careers) Program has announced ... of America,s 27th Annual Mouse Molecular Genetics Conference ... Pacific Grove, California. These awards are meant ... and scientists from underrepresented groups into the mainstream ... the participation of young scientists at the Genetics ...
(Date:8/28/2014)... N.C. -- Scientists have identified the developmental on-off switch ... that produce more than two-thirds of the world,s naturally ... be to see whether it is possible to manipulate ... , The study, appearing August 28 in ... small molecule called cyclic-di-GMP and a larger protein called ...
Breaking Biology News(10 mins):New tool aids stem cell engineering for medical research 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... State University researchers have uncovered a pattern of distrust ... hospitals and midwives who are transporting their home-birth clients ... State University assistant professor Melissa Cheyney and doctoral student ... between physicians and midwives that is reflective of discord ...
... Phase I SBIR grant of $1,296,403 from the ... "Differential Phase Contrast Imaging" using the unique x-ray ... The grant will allow Lyncean to continue ... and its applications to new methods of imaging ...
... built a new tissue scaffold that can stimulate bone ... other joints. The scaffold could offer a potential ... such as arthritis, says Lorna Gibson, the Matoula S. ... of the research team with Professor William Bonfield of ...
Cached Biology News:Study reveals conflict between doctors, midwives over homebirth 2Study reveals conflict between doctors, midwives over homebirth 3Lyncean Technologies Inc. receives $1.2 M from NCRR to develop new imaging technique 2MIT: New tissue scaffold regrows cartilage and bone 2
... Conjugate Stabilizer is an aqueous solution that ... non-toxic stabilizing chemicals in a MOPS buffer ... This product contains a combination of ... Proclin 300 (Rohm and Haas Company) as ...
Preparation Note: by a modification of the procedure of C.W. Hancher et al., Biotechnol. Bioeng. 11, 1055 (1969) Assay: ~ 20 A 260 /mg Solubility: water 10 mg/mL, clear, light-yellow Suitab tst...
Request Info...
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
Biology Products: